A copper-hydrogen peroxide redox system induces dityrosine cross-links and chemokine oligomerisation

Cytokine

Volumn 56, Issue 3, 2011, Pages 669-675

  MacGregor, Helen J ^a   Kato, Yoji ^b   Marshall, Lindsay J ^a   Nevell, Thomas G ^a   Shute, Janis K ^a  

^a UNIVERSITY OF PORTSMOUTH   (United Kingdom)

^b UNIVERSITY OF HYOGO   (Japan)

Author keywords

Chemokine; Copper; Dityrosine; Heparan sulphate; Redox

Indexed keywords

CHEMOKINE; COPPER; DIMER; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; HEPARIN; HYDROGEN PEROXIDE; INTERLEUKIN 8; IRON; MERCURY; MONOMER; NICKEL; OLIGOMER; RANTES; TETRAMER; TYROSINE; ZINC;

ARTICLE; CELL MIGRATION; COMPLEX FORMATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; COVALENT BOND; CROSS LINKING; FLUORESCENCE SPECTROSCOPY; HUMAN; HUMAN CELL; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; OLIGOMERIZATION; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, NEUTRALIZING; BIOLOGICAL ASSAY; BLOTTING, WESTERN; CATTLE; CHEMOKINE CCL5; CHROMATOGRAPHY, LIQUID; COPPER; CROSS-LINKING REAGENTS; HUMANS; HYDROGEN PEROXIDE; MASS SPECTROMETRY; OXIDATION-REDUCTION; PROTEIN MULTIMERIZATION; RECEPTORS, CCR3; RECEPTORS, CCR5; REFERENCE STANDARDS; SERUM ALBUMIN, BOVINE; SPECTROMETRY, FLUORESCENCE; TYROSINE;

EID: 81455158817     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2011.08.025     Document Type: Article

References (46)

1. Proudfoot A.E.I. Chemokine receptors: multifaceted therapeutic targets. Nat Rev Immunol 2002, 2:106-115.
2. Parish C.R. The role of heparan sulphate in inflammation. Nat Rev Immunol 2006, 6:633-643.
3. Hoogewerf A.J., Kuschert G.S.V., Proudfoot A.E.I., Borlat F., Clark-Lewis I., Power C.A., et al. Chemokines. Biochemistry 1997, 36:13570-13578.
4. Kuschert G.S.V., Coulin F., Power C.A., Proudfoot A.E.I., Hubbard R.E., Hoogewerf A.J., et al. Glycosaminoglycans interact selectively with chemokines and modulate receptor binding and cellular responses. Biochemistry 1999, 38:12959-12968.
5. Proudfoot A.E.I., Handel T.M., Johnson Z., Lau E.K., LiWang P., Clark-Lewis I., et al. Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines. Proc Natl Acad Sci 2002, 100:1885-1890.
6. Atwood C.S., Perry G., Zeng H., Kato Y., Jones W.D., Ling K.-Q., et al. Copper mediates dityrosine cross-linking of Alzheimer's amyloid-beta. Biochemistry 2004, 43:560-568.
7. van Horssen J., Wesseling P., Van den Heuvel L.P.W.J., de Waal R.M.W., Verbeek M.M. Heparan sulphate proteoglycans in Alzheimer's disease and amyloid-related disorders. Lancet Neurol 2003, 2:482-492.
8. Fernandez E.J., Lolis E. Structure, function and inhibition of chemokines. Annu Rev Pharmacol Toxicol 2002, 42:469-499.
9. Czaplewski L.G., McKeating J., Craven C.J., Higgins L.D., Appay V., Brown A., et al. Identification of amino acid residues critical for aggregation of human CC chemokines macrophage inflammatory protein (MIP)-1α, MIP-1β, and RANTES. J Biol Chem 1999, 274:16077-16084.
10. Kim B.-E., Nevitt T., Thiele D.J. Mechanisms for copper acquisition, distribution and regulation. Nat Chem Biol 2008, 4:176-185.
11. Brewer G.J. The risks of free copper in the body and the development of useful anticopper drugs. Curr Opin Clin Nutr Metab Care 2008, 11:727-732.
12. Lamb D.J., Leake D.S. Acidic pH enables caeruloplasmin to catalyse the modification of low-density lipoprotein. FEBS Lett 1994, 338:122-126.
13. Persichini T., Percario Z., Mazzon E., Colasanti M., Cuzzocrea S., Musci G. Copper activates the NF-κB pathway in vivo. Antioxid Redox Signaling 2006, 8:1897-1904.
14. Bar-Or D., Thomas G.W., Yuki R.L., Rael L.T., Shimonkevitz R.P., Curtis C.G., et al. Copper stimulates the synthesis and release of interleukin-8 in human endothelial cells: a possible early role in systemic inflammatory responses. Shock 2003, 20:154-158.
15. Spisni E., Valerii M.C., Manerba M., Strillacci A., Polazzi E., Mattia T., et al. Effect of copper on extracellular levels of pro-inflammatory molecules in hypothalamic GN11 and primary neurons. Neurotoxicol 2009, 30:605-612.
16. Kato Y., Wu X., Naito M., Nomura H., Kitamoto N., Osawa T. Immunochemical detection of protein dityrosine in atherosclerotic lesion of Apo-E-deficient mice using a novel monoclonal antibody. Biochem Biophys Res Commun 2000, 275:11-15.
17. Kato Y., Dozaki N., Nakamura T., Kitamoto N., Yoshida A., Naito M., et al. Quantification of modified tyrosines in healthy and diabetic human urine using liquid chromatography/tandem mass spectrometry. J Clin Biochem Nutr 2009, 44:67-78.
18. Loetscher P., Seitz M., Baggiolini M., Moser B. Interleukin-2 regulates CC chemokine receptor expression and chemotactic responsiveness in T lymphocytes. J Exp Med 1996, 184:569-577.
19. Fox J.H., Kama J.A., Lieberman G., Chopra R., Dorsey K., Chopra V., et al. Mechanisms of copper ion mediated Huntington's disease progression. PLOS One 2007, 2:e334.
20. Arai H., Kashiwagi S., Nagasaka Y., Uchida K., Hoshii Y., Nakamura K. Oxidative modification of apolipoprotein E in human very-low-density lipoprotein and its inhibition by glycosaminoglycans. Arch Biochem Biophys 1999, 367:1-8.
21. Kato Y., Kitamoto N., Kawai Y., Osawa T. The hydrogen peroxide/copper ion system, but not other metal-catalyzed oxidation systems, produces protein-bound dityrosine. Free Rad Biol Med 2001, 31:624-632.
22. Versieck J., Barbier F., Speecke A., Hoste J. Manganese, copper, and zinc concentrations in serum and packed blood cells during acute hepatitis, chronic hepatitis, and posthepatitic cirrhosis. Clin Chem 1974, 20:1141-1145.
23. Halliwell B., Clement M.V., Ramalingam J., Long L.H. Hydrogen peroxide. Ubiquitous in cell culture and in vivo?. IUBMB Life 2000, 50:157-251.
24. Halliwell B., Clement M.V., Long L.H. Hydrogen peroxide in the human body. FEBS Lett 2000, 486:10-13.
25. Percival S.S. Copper and immunity. Am J Clin Nutr 1998, 67:1064S-1068S.
26. Skelton N.J., Aspiras F., Ogez J., Schall T.J. Proton NMR assignments and solution conformation of RANTES. A chemokine of the C-C type. Biochemistry 1995, 34:5329-5342.
27. Burrows S.D., Doyle M.L., Murphy K.P., Franklin S.G., White J.R., Brooks I., et al. Determination of the monomer-dimer equilibrium of interleukin-8 reveals it is a monomer at physiological concentrations. Biochemistry 1994, 33:12741-12745.
28. Rehm M., Bruegger D., Christ F., Conzen P., Thiel M., Jacob M., et al. Shedding of the endothelial glycocalyx in patients undergoing major vascular surgery with global and regional ischemia. Circulation 2007, 116:1896-1906.
29. Scully M.F., Ellis E., Kakkar V.V. Heparan sulphate with no affinity for antithrombin III, the control of haemostasis. FEBS Lett 1988, 241:11-14.
30. Reeves EP, Williamson M, O'Neill SJ, Greally P, McElvaney NG. Nebulised hypertonic saline decreases interleukin-8 in sputum of patients with cystic fibrosis. Am J Respir Crit Care Med 2011;epub.
31. Sadir R., Imberty A., Baleux F., Lortat-Jacob H. Heparan sulphate/heparin oligosaccharides protect stromal cell-derived factor-1 (SDF-1)/CXCL12 against proteolysis induced by CD26/dipeptidyl peptidase IV. J Biol Chem 2004, 279:43854-43860.
32. Mukherjee D.C., Park J.W., Chakrabati B. Optical properties of Cu(II) complexes with heparin and related glycosaminoglycans. Arch Biochem Biophys 1978, 191:393-399.
33. Dokmanic I., Sikic M., Tomic S. Metals in proteins: correlation between the metal-ion type, coordination number and the amino-acid residues involved in the coordination. Acta Cryst 2008, D64:257-263.
34. Camakaris J., Voskoboinik I., Mercer J.F. Molecular mechanisms of copper homeostasis. Biochem Biophys Res Commun 1999, 261:225-232.
35. Barry A., Clark K.M., Otoikhian A., VanderDonk W.A., Blackburn N.J. Selenocysteine positional variants reveal contributions to copper binding from cysteine residues in domains 2 and 3 of human copper chaperone for superoxide dismutase. Biochemistry 2008, 47:13074-13083.
36. Bush A.I., Tanzi R.E. Therapeutics for Alzheimer's disease based on the metal hypothesis. Neurotherapeutics 2008, 5:421-431.
37. von Luettichau I., Nelson P.J., Pattison J.M., van der Rijn M., Huie P., Warnke R., et al. RANTES chemokine expression in diseased and normal tissues. Cytokine 1996, 8:89-98.
38. Patel S.R., Hartwig J.H., Italiano J.E. The biogenesis of platelets from megakaryocyte proplatelets. J Clin Invest 2005, 115:3348-3354.
39. Schmitt Y. Copper and zinc determination in plasma and corpuscular components of peripheral blood of patients with preterminal and terminal renal failure. J Trace Elements Med Biol 1997, 11:210-214.
40. Baltus T., von Hundelshausen P., Mause S.F., Buhre W., Rossaint R., Weber C. Differential and additive effects of platelet-derived chemokines on monocyte arrest on inflamed endothelium under flow conditions. J Leuk Biol 2008, 78:435-441.
41. Weingart C, Nelson PJ, Kramer BK, Mack M. Dose dependent effects of platelet derived chondroitin sulfate A on the binding of CCL5 to endothelial cells, BMC Immunol 2008;9:72.
42. Sallusto F., Lanzavecchia A., Mackay C.R. Chemokines and chemokine receptors in T-cell priming and Th1/Th2-mediated responses. Immunol Today 1998, 18:568-574.
43. Pakianathan D.R., Kuta E.G., Artis D.R., Skelton N.J., Hebert C.A. Distinct but overlapping epitopes for the interaction of a CC-chemokine with CCR1, CCR3, and CCR5. Biochemistry 1997, 36:9642-9648.
44. Trkola A., Gordon C., Matthews J., Maxwell E., Ketas T., Czaplewski L., et al. The CC-chemokine RANTES increases the attachment of human immunodeficiency virus type I to target cells via glycosaminoglycans and also activates a signal transduction pathway that enhances viral infectivity. J Virol 1999, 73:6370-6379.
45. Van A., der Vliet M.N., Nguyen M.K., Shigenaga J.P., Eiserich G.P., Marelich C.E., et al. Myeloperoxidase and protein oxidation in cystic fibrosis. Am J Physiol Lung Cell Mol Physiol 2000, 279:L537-L546.
46. Heinecke J.W. Tyrosyl radical production by myeloperoxidase: a phagocyte pathway for lipid peroxidation and dityrosine cross-linking of proteins. Toxicology 2002, 177:11-22.